• Adia Med’s lab subsidiary, Adia Labs, expanded its regenerative research-use product lineup with three new offerings.
• New products add lower cell-count stem cells, an ophthalmic or otic exosome format, or a lower-concentration exosome option.
• Adia Labs positioned the additions to broaden study-design choices for physicians using IRB-approved or similarly authorized protocols.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adia Med Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609290800NEWSFILECNPR____20260929_316434_1) on September 29, 2026, and is solely responsible for the information contained therein.